Tadalafil USP For Compounding (API)

Tadalafil USP for Compounding (API) is an active pharmaceutical ingredient used in the preparation of customized medications primarily for the treatment of erectile dysfunction (ED) and benign prostatic hyperplasia (BPH). As a phosphodiesterase type 5 (PDE5) inhibitor, tadalafil increases blood flow to specific areas by relaxing blood vessels, facilitating erections in response to sexual stimulation, and improving symptoms of BPH such as urinary frequency and urgency. It may also be used for pulmonary arterial hypertension (PAH) management, offering an option to tailor dosage forms and strengths to meet unique patient needs and improve therapeutic outcomes.

Tadalafil USP is a specific grade of tadalafil, which is an active pharmaceutical ingredient (API) used in the manufacturing of medications for the treatment of erectile dysfunction (ED) and benign prostatic hyperplasia (BPH). API refers to the biologically active component in a drug substance that produces the intended therapeutic effect. In the case of tadalafil USP, it acts as a phosphodiesterase type 5 (PDE5) inhibitor, which helps relax smooth muscles and increases blood flow to the penis, leading to improved erectile function. Tadalafil USP must meet specific quality and purity standards set by the USP to be used in pharmaceutical products for human consumption. 

Tadalafil USP is used for compounding to make custom medication formulations for the treatment of erectile dysfunction (ED) and benign prostatic hyperplasia (BPH). It is a phosphodiesterase type 5 (PDE5) inhibitor that works by increasing blood flow to the penis, improving the ability to achieve and maintain an erection. It can also help with BPH symptoms such as difficult or frequent urination. Tadalafil USP may be used in combination with other compounds as recommended by a healthcare provider for individualized treatment options.

CAS Number: 171596-29-5
Property: Light Sensitive